Midatech Pharma (MTPH)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.25p
   
  • Change Today:
    -0.15p
  • 52 Week High: 11.50
  • 52 Week Low: 2.20
  • Currency: UK Pounds
  • Shares Issued: 469.90m
  • Volume: 950,319
  • Market Cap: £10.57m
  • RiskGrade: 395
  • Beta: 0.02

Deal with Barclays    Trade now with Barclays Stockbrokers

Midatech reveals positive results from 'MTX102' human study

By Josh White

Date: Friday 19 Jul 2019

LONDON (ShareCast) - (Sharecast News) - Midatech Pharma announced positive results from a first-in-human study of its 'MTX102' immuno-tolerising vaccine product candidate in diabetes on Friday.
The AIM-traded firm said the focus of the phase 1 study was to assess the safety of MTX102, with five recently-diagnosed type-1 diabetes patients, all meeting strict genetic parameters, recruited onto the study and receiving the study drug.

MTX102 was said to have been well-tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events reported.

The board said it was an important study of systemic injectable administration of Midatech's gold nanoparticle technology, 'MidaCore'.

It explained that it provided promising safety validation of the MidaCore technology as a platform for the development of medications for use in humans.

"This EU project brings together a consortium comprising eight complementary partners, including two small and medium enterprises, one technology transfer company and five academic laboratories, from four EU states - UK, France, the Netherlands and Sweden - and Israel," said principal investigator Colin Dayan.

"We are pleased to have completed the initial project, based on Midatech's gold nanoparticle technology, to evaluate a vaccine approach for the treatment of type-1 diabetes.

"The study now enters a follow up stage, at the end of which we will review the data and programme, together with the EU consortium partners."

Craig Cook, chief executive officer of Midatech Pharma, added that the EU-funded programme was an "invaluable" project to further develop, understand and evaluate Midatech's gold nanoparticle technology, MidaCore.

"This is the first human study to assess the safety of MidaCore when injected into patients, and we are pleased that the data generated to date validates the technology as a potentially innovative treatment platform for medical applications," Cook said.

The company said the aim of the study to assess safety had been achieved, and no further patients would be recruited.

All patients on the trial would now enter the follow-up phase, which would conclude around the first quarter of 2020.

MTX102 was based on Midatech's MidaCore technology platform of "ultra-small" gold nanoparticle drug conjugates.

MidaCore was being developed as an immunotherapeutic, as well as a chemotherapeutic platform.

In vaccines, Midatech said it represented an "innovative" approach that took advantage of the multifunctional properties of gold nanoparticles, to combine immunogenic peptides and tolerising agents and deliver them more efficiently to immune cells in order to dampen down autoimmune responses in diseases such as diabetes.

Midatech was part of a consortium of academic institutions and industry partners investigating the potential of MTX102 as a vaccine to prevent or limit the damage that occurred when the body attacks its own insulin-producing cells in the pancreas.

The project was funded by the European Union up to the completion of the phase 1 study.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

MTPH Market Data

Currency UK Pounds
Share Price 2.25p
Change Today -0.15p
% Change -6.25 %
52 Week High 11.50
52 Week Low 2.20
Volume 950,319
Shares Issued 469.90m
Market Cap £10.57m
Beta 0.02
RiskGrade 395

MTPH Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.58% above the market average22.58% above the market average22.58% above the market average22.58% above the market average22.58% above the market average
32.20% above the sector average32.20% above the sector average32.20% above the sector average32.20% above the sector average32.20% above the sector average
Price Trend
96.26% below the market average96.26% below the market average96.26% below the market average96.26% below the market average96.26% below the market average
89.83% below the sector average89.83% below the sector average89.83% below the sector average89.83% below the sector average89.83% below the sector average
Income Not Available
Growth
35.82% above the market average35.82% above the market average35.82% above the market average35.82% above the market average35.82% above the market average
36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average

MTPH Dividends

No dividends found

Trades for 10-Dec-2019

Time Volume / Share Price
14:11 136,925 @ 2.20p
13:46 35,946 @ 2.22p
12:52 71,719 @ 2.29p
12:47 8,340 @ 2.22p
12:46 16,981 @ 2.22p

MTPH Key Personnel

CEO Craig Cook
CFO Stephen Stamp

Top of Page